-
Orchestra BioMed Inc. (OBIO) PT Lowered to $10 at H.C. Wainwright
-
Orchestra BioMed publishes clinical data on blood pressure therapy
-
BTIG Downgrades Orchestra BioMed Inc. (OBIO) to Neutral
-
Orchestra BioMed reports therapy improved heart function in hypertension study
-
Orchestra BioMed (OBIO) Misses Q2 EPS by 50c
-
Orchestra BioMed expands patient eligibility for hypertension study
-
Orchestra BioMed raises $111 million through equity offerings and partnerships
-
Ligand and Medtronic invest $70 million in Orchestra BioMed
-
Orchestra BioMed (OBIO) Misses Q1 EPS by 49c
-
Orchestra BioMed Inc. (OBIO) PT Lowered to $12 at Barclays
-
Orchestra BioMed (OBIO) Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing Virtue SAB
-
H.C. Wainwright Reiterates Buy Rating on Orchestra BioMed Inc. (OBIO)
-
Orchestra BioMed (OBIO) Receives FDA Breakthrough Device Designation for AVIM Therapy
-
Orchestra BioMed Inc. (OBIO) PT Lowered to $12 at H.C. Wainwright
-
BTIG Reiterates Buy Rating on Orchestra BioMed Inc. (OBIO)
-
BTIG Starts Orchestra BioMed Inc. (OBIO) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Orchestra BioMed Inc. (OBIO)
-
Orchestra BioMed (OBIO) Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at
-
Barclays Starts Orchestra BioMed Inc. (OBIO) at Overweight
-
H.C. Wainwright Starts Orchestra BioMed Inc. (OBIO) at Buy

